Get the Stockscreener App
2.46
3.53%
-0.09
After Hours:
2.42
-0.04
-1.63%
Cyclerion Therapeutics Inc stock is traded at $2.46, with a volume of 24,256.
It is down -3.53% in the last 24 hours and up +2.50% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$2.55
Open:
$2.55
24h Volume:
24,256
Relative Volume:
0.67
Market Cap:
$8.21M
Revenue:
$556.00K
Net Income/Loss:
$-5.28M
P/E Ratio:
-1.1495
EPS:
-2.14
Net Cash Flow:
$-6.23M
1W Performance:
+11.05%
1M Performance:
+2.50%
6M Performance:
-3.53%
1Y Performance:
-22.21%
1-Day Range:
$2.40
$2.5501
1-Week Range:
$2.1301
$2.62
52-Week Range:
$1.27
$9.4699
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
2.46 | 7.57M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
Using RSI to spot recovery in Cyclerion Therapeutics Inc.2025 Key Lessons & Safe Capital Allocation Plans - newser.com
Is this a good reentry point in Cyclerion Therapeutics Inc.IPO Watch & Entry Point Strategy Guides - newser.com
Using economic indicators to assess Cyclerion Therapeutics Inc. potentialTrade Performance Summary & Precise Buy Zone Tips - newser.com
Cyclerion Therapeutics Inc.’s volatility index tracking explained2025 Stock Rankings & Community Trade Idea Sharing Platform - Newser
Cyclerion Therapeutics Inc. stock retracement – recovery analysisWeekly Investment Report & Weekly High Conviction Ideas - Newser
Long term hold vs stop loss in Cyclerion Therapeutics Inc.Inflation Watch & Weekly Stock Performance Updates - Newser
Signal strength of Cyclerion Therapeutics Inc. stock in tech scannersEarnings Trend Report & Weekly Breakout Watchlists - Newser
Chart based analysis of Cyclerion Therapeutics Inc. trendsPortfolio Update Report & Fast Momentum Stock Entry Tips - Newser
Custom strategy builders for tracking Cyclerion Therapeutics Inc.Insider Buying & Breakout Confirmation Trade Signals - Newser
Is Cyclerion Therapeutics Inc. trending in predictive chart modelsJuly 2025 News Drivers & Risk Adjusted Buy/Sell Alerts - Newser
Using Python tools to backtest Cyclerion Therapeutics Inc. strategiesTrade Analysis Report & Short-Term Trading Opportunity Alerts - Newser
Applying Wyckoff theory to Cyclerion Therapeutics Inc. stockJuly 2025 Outlook & Fast Entry and Exit Trade Plans - Newser
Is a relief rally coming for Cyclerion Therapeutics Inc. holders2025 Major Catalysts & Daily Stock Trend Reports - Newser
Does Cyclerion Therapeutics Inc. qualify in momentum factor screening2025 Earnings Surprises & Risk Adjusted Buy/Sell Alerts - Newser
Can volume confirm reversal in Cyclerion Therapeutics Inc.July 2025 PostEarnings & Stepwise Swing Trade Plans - Newser
Cyclerion Therapeutics Inc. stock outlook for YEARMarket Activity Recap & Precise Entry and Exit Recommendations - Newser
Analyzing Cyclerion Therapeutics Inc. with multi timeframe charts2025 Short Interest & Intraday High Probability Setup Alerts - Newser
Forecasting Cyclerion Therapeutics Inc. price range with options dataQuarterly Profit Review & Consistent Profit Trading Strategies - Newser
cyclerion therapeutics inc.’s volatility index tracking explainedJuly 2025 Closing Moves & Safe Entry Point Identification - Newser
Chart based exit strategy for Cyclerion Therapeutics Inc.Trade Exit Report & Verified Short-Term Trading Plans - Newser
Understanding Cyclerion Therapeutics Inc.’s price movement2025 Earnings Impact & Consistent Return Investment Signals - Newser
Candlestick signals on Cyclerion Therapeutics Inc. stock today2025 Market Overview & Fast Moving Stock Watchlists - Newser
Is Cyclerion Therapeutics Inc. forming a reversal patternJuly 2025 WrapUp & Expert Curated Trade Setup Alerts - Newser
Can Cyclerion Therapeutics Inc. recover in the next quarterPortfolio Value Summary & Stepwise Swing Trade Plans - Newser
How to forecast Cyclerion Therapeutics Inc. trends using time seriesJuly 2025 Recap & Free Technical Pattern Based Buy Signals - Newser
Backtesting results for Cyclerion Therapeutics Inc. trading strategiesWeekly Investment Summary & Fast Entry High Yield Stock Tips - Newser
Analyzing net buyer seller activity in Cyclerion Therapeutics Inc. - Newser
Using data tools to time your Cyclerion Therapeutics Inc. exitWeekly Trend Report & Technical Entry and Exit Tips - Newser
Will Cyclerion Therapeutics Inc. outperform the marketJuly 2025 Market Mood & Low Drawdown Momentum Ideas - Newser
Does Cyclerion Therapeutics Inc. meet Warren Buffett’s criteriaRecession Risk & AI Driven Stock Price Forecasts - Lancaster City Council
Institutional scanner results for Cyclerion Therapeutics Inc.Portfolio Growth Summary & Fast Gaining Stock Reports - Newser
Fibonacci Retracement Aligns with Support in Cyclerion Therapeutics Inc.July 2025 Gainers & Weekly High Potential Alerts - beatles.ru
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):